GDC-0068: Phase Ib/II started
Roche's Genentech Inc. unit began an international Phase Ib/II trial of GDC-0068 or GDC-0980 ( RG7422) in 262 CRPC patients previously treated with docetaxel. The open-label Phase Ib portion will determine the recommended Phase II dose of GDC-0068 and GDC-0980 each in combination with abiraterone and prednisone/prednisolone. The double-blind, placebo-controlled Phase II portion will compare GDC-0068 or GDC-0980 with abiraterone and prednisone/prednisolone vs. abiraterone and prednisone/prednisolone alone.
Genentech and Array discovered GDC-0068, which is also in Phase I testing for solid tumors. GDC-0980 is in Phase II testing for various cancers, including endometrial carcinoma and metastatic renal cell carcinoma. GDC-0980 is a dual inhibitor of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin ( mTOR). GDC-0068 is a small molecule inhibitor of protein kinase B (PKB; PKBA; AKT; AKT1), AKT2 and AKT3. ...